TECELRA

Serial Number 90452726
Registration 6823692
700

Registration Progress

Application Filed
Jan 7, 2021
Under Examination
Approved for Publication
Jun 7, 2022
Published for Opposition
Jun 7, 2022
Registered
Aug 23, 2022

Trademark Image

TECELRA

Basic Information

Serial Number
90452726
Registration Number
6823692
Filing Date
January 7, 2021
Registration Date
August 23, 2022
Published for Opposition
June 7, 2022
Drawing Code
4

Status Summary

Current Status
Active
Status Code
700
Status Date
Aug 23, 2022
Registration
Registered
Classes
005 044

Rights Holder

USWM CT, LLC

16
Address
4441 SPRINGDALE ROAD
LOUISVILLE, KY 40241

Ownership History

Adaptimmune Limited

Original Applicant
99
Oxford GB

Adaptimmune Limited

Owner at Publication
99
Oxford GB

Adaptimmune Limited

Original Registrant
99
Oxford GB

USWM CT, LLC

New Owner After Registration #1
16
LOUISVILLE, KY

Legal Representation

Attorney
Amy B. Berge

USPTO Deadlines

Next Deadline
970 days remaining
Section 8 Declaration Due (Principal Register) (Based on registration date 20220823)
Due Date
August 23, 2028
Grace Period Ends
February 23, 2029
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

29 events
Date Code Type Description Documents
Dec 8, 2025 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Dec 8, 2025 EWOR I TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED Loading...
Dec 8, 2025 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Dec 8, 2025 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Dec 8, 2025 CHAN I APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Loading...
Dec 8, 2025 COAR I TEAS CHANGE OF OWNER ADDRESS RECEIVED Loading...
Sep 3, 2025 ASGN I AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP Loading...
Aug 23, 2022 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED Loading...
Aug 23, 2022 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Jun 7, 2022 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Jun 7, 2022 PUBO A PUBLISHED FOR OPPOSITION Loading...
May 18, 2022 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Apr 29, 2022 FIXD O ELECTRONIC RECORD REVIEW COMPLETE Loading...
Mar 30, 2022 ERRR O ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED Loading...
Mar 11, 2022 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Feb 10, 2022 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Feb 10, 2022 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Feb 8, 2022 ALIE A ASSIGNED TO LIE Loading...
Feb 8, 2022 ERSI I TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED Loading...
Jul 19, 2021 GNS3 O NOTIFICATION OF LETTER OF SUSPENSION E-MAILED Loading...
Jul 19, 2021 GNSL S LETTER OF SUSPENSION E-MAILED Loading...
Jul 19, 2021 CNSL R SUSPENSION LETTER WRITTEN Loading...
Jul 19, 2021 XAEC I EXAMINER'S AMENDMENT ENTERED Loading...
Jul 19, 2021 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Loading...
Jul 19, 2021 GNEA F EXAMINERS AMENDMENT E-MAILED Loading...
Jul 19, 2021 CNEA R EXAMINERS AMENDMENT -WRITTEN Loading...
Jul 16, 2021 DOCK D ASSIGNED TO EXAMINER Loading...
Apr 6, 2021 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Jan 11, 2021 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Cell therapy pharmaceutical preparations; immunotherapy preparations; T-cell receptors; immunotherapy preparations comprising engineered T-cell Cell therapy pharmaceutical preparations for use in cancer treatment; pharmaceutical immunotherapy preparations for use in cancer treatment; T-cell receptors, namely, pharmaceutical preparations for use in cancer treatment; pharmaceutical immunotherapy preparations comprising engineered T-cell receptors for use in cancer treatment; pharmaceutical immunotherapy preparations comprising genes encoding engineered T-cell receptors for use in cancer treatment
Class 044
Cell therapy medical treatment services; Medical services, namely, immunotherapy services; Medical services, namely, medical treatment and immune-therapy comprising harvesting a patient's white blood cells, combining white blood cells with an engineered T-cell receptor therapeutic, transducing the white blood cells with the gene encoding the engineered T-cell receptor and infusion of the transduced white blood cells back into the patient

Classification

International Classes
005 044